

## ATB-610: Small molecule developing as a inhaler with reducing toxicity by inhibiting ALK5 selectively for IPF treatment



RESPIRATORY	Candidate
Product Type	Small molecule
Indication	Idiopathic Pulmonary Fibrosis
Target	ALK5 (TGF- $\beta$ R1)
MoA(Mechanism of Action)	Inhibiting the Transition of lung fibroblast to myofibroblast by inhibiting TGF- $\beta$
Competitiveness	<ul style="list-style-type: none"> <li>- Derivation of the most selective ALK5 inhibitor among ALK family</li> <li>- Securing selectivity for other kinases and receptors other than TFG-<math>\beta</math></li> <li>- Resolves concerns about on-target toxicity of TGF-<math>\beta</math> inhibition through topical action and inhalation development</li> </ul>
Development Stage	Candidate
Route of Administration	Inhalation